Dr Urvi Shah speaks to ecancer about her study presented at ASH 2024.

This study investigates a high-fibre dietary intervention for patients with monoclonal gammopathy of undetermined significance and smouldering myeloma, aiming to delay disease progression.

Involving 20 patients, the pilot study achieves a 7-8% weight loss and maintains dietary adherence for over a year.

Biomarker analysis shows metabolic improvements and positive immune function changes.

Future research plans to expand the study to over 150 patients to explore dietary supplements' effects.